ClinicalTrials.gg
RecruitingNCT07185425Updated Nov 12, 2026

Impact of the NeuroCuple Device on Pain Management After Cesarean Delivery

An interventional study of NeuroCuple and Sham in Pain, Analgesia and Pregnancy, sponsored by Inova Health Care Services. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Inova Health Care Services · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
541st of 2,564
180 · median 66
Started
2025
with 128 others
No phase
1,244 of 2,886
183 open now
Primary completion
2027-09
later than 243 of 392 live
Registered
2,764th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 541st largest by planned enrollment of the 2,564 interventional ones that give a count, is one of 129 that started in 2025, is one of 1,244 with no phase, reaches primary completion later than 243 of the 392 other live ones, and was the 2,764th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

This will be a single-center, sham-controlled, 3 arms, randomized (1:1:1) prospective study in females undergoing cesarean delivery to investigate the impact of NeuroCuple™ non-pharmacological analgesic device for management of postoperative pain. The investigators hypothesize that women treated with the Neurocuple device will experience less pain and consequently require less opioid pain medication after cesarean delivery compared to women who receive standard post-surgical medication.

Read the detailed description

This is a single-center, sham-controlled, 3-arms, randomized, prospective study in 180 women undergoing cesarean delivery, with an expected subject enrollment duration of one year. Subjects will be screened and consented preoperatively before the scheduled case. Enrolled subjects will be randomized by research personnel using a computer generated randomization scheme in a 1:1:1 group allocation and assigned to the active device, sham device, or standard of care arms.

Upon arrival to the PACU, subjects in the standard-of-care arm will receive standard postoperative pain orders at the discretion of the primary OB/GYN. For subjects in the active and sham device arms, device will be placed as soon as feasible in the PACU and before transfer to the post-partum floor by trained research staff. Both patients and the clinical team will be blinded to the group assignment for the active and sham devices.

Pain scores will be collected from the study participants per nursing protocols while inpatient, and daily after discharge until postoperative day 4, using the Pain Numeric Rating Scale. For breakthrough pain, patients may use oral or IV opioids in the inpatient setting and oral opioids in the outpatient setting.

Upon discharge, patients are typically prescribed an opioid medication. However, this will also be left to the discretion of the primary OB/GYN. In this study, the investigators will examine total milligram morphine equivalent (MME) opioid intake at postoperative day 4 or before discharge as the primary endpoint, reduction (percentage change) in numeric pain scale as the secondary endpoint, and change in quality of recovery as the exploratory endpoint.

03

Conditions studied

  • Pain
  • Analgesia
  • Pregnancy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female 18 years or older able to provide in English or Spanish
  • Scheduled for a planned or unplanned non-emergent cesarean delivery under neuraxial anesthesia
  • Intact skin surfaces around the operative skin incision area at the site of patch application
  • Pfannestiel skin incision

Exclusion criteria

Exclusion Criteria:

  • Active drug abuse
  • Chronic opioid user
  • Severe chronic pain
  • Psoriasis vulgaris or other skin conditions precluding safe device application
  • Subject is concurrently participating in another research study with an drug or medical device that in the Investigator's opinion could impact subject safety or study results
  • Subject with reasons to maintain an epidural beyond operative room
  • Subject with complex surgery or subject who may need more than a cesarean surgery with possible tubal sterilization procedure
  • Subject is deemed not suitable for the study at the discretion of the principal Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    NeuroCuple device

    Device placed by research personnel in PACU prior to transfer to the post-partum unit

    Device: NeuroCuple

  • Sham comparator
    Sham device

    Device placed by research personnel in PACU prior to transfer to the post-partum unit

    Device: Sham

  • No intervention
    Standard of care

    No device will be placed

Interventions

  • DeviceNeuroCuple

    Device around the abdomen over c-section bandages in the PACU

  • DeviceSham

    Device around the abdomen over c-section bandages in the PACU

06

What researchers measure

Primary outcomes

  1. Total Milligram Morphine Equivalents (MME)

    Total opioid intake in MME on postoperative days 4 or before discharge.

    Time frame: Day of surgery to postop day 4

Secondary outcomes

  1. Pain reduction

    Reduction (percentage decrease) in pain score (0-10 numeric rating scale) from day of surgery through postoperative day 4.

    Time frame: Day of surgery to postop day 4

  2. Quality of Recovery

    Quality of recovery assessment evaluated on postoperative days 1-4 (Swedish Web Version of Quality of Recovery (SwQoR))

    Time frame: Day of surgery to postop day 4

  3. Opioid-related adverse events

    Overall incidence of opioid-related adverse effects including maternal PONV, sedation, constipation in POD 0-4

    Time frame: Day of surgery to postop day 4

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Do not plan to share IPD

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 23 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 22, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07185425
Lead sponsor
Inova Health Care Services
Collaborators
nCap Medical
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Oct 13, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Antonio Saad, MD
Contact
antonio.saad@inova.org
7037766040
Michelle Cassidy, phD
Contact
michelle.cassidy@inova.org
7037764600
Antonio Saad, MD
principal investigator · Inova Health Care Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion